Premature ovarian insufficiency: an International Menopause Society White Paper

Abstract

The aim of this International Menopause Society White Paper on premature ovarian insufficiency (POI) is to provide the latest information regarding this distressing condition. The impact of POI has far-reaching consequences due to its impact on general, psychological, and sexual quality of life, fertility prospects, and long-term bone, cardiovascular, and cognitive health. Progress in fully understanding the etiology, diagnosis, and optimal management options has been slow thus far due to the complexity of the condition and fragmented research. Recent advances in epidemiological and genetic research have improved our understanding of this condition and randomized prospective trials are being planned to determine the intervention strategies, which will optimize quality of life and long-term well-being. The International Menopause Society has commissioned a number of experts at the forefront of their specialty to define the state of the art in the understanding of this condition, to advise on practical management strategies, and to propose future research strategies. It is hoped that a global task force will subsequently be convened in order to formulate a consensus statement across key societies, to accelerate date collection and analysis of a global POI registry, and to facilitate progress in the key defined areas of research.

摘要

这篇国际绝经学会关于早发性卵巢功能不全（POI）的白皮书的目的是提供一些关于该病的最新信息以及目前令人堪忧的状况。由于POI对患者一般生活、心理和性生活质量、生育前景以及长期骨骼、心血管和认知健康的影响, 因此具有深远的意义。到目前为止, 由于病情的复杂性和研究的分散, 对病因、诊断和最佳治疗方案的全面了解进展缓慢。流行病学和遗传学研究的最新进展增加了我们对这种状况的理解, 并且计划进行随机前瞻性实验以确定干预策略、优化生活质量及提高幸福感。国际绝经学会已经委任了一些专业前沿的专家来定义对这一状况的理解, 对实际疾病的管理策略提出建议, 并提出未来研究的策略。希望随后将召集一个全球工作组, 以便在关键学会之间形成共识性声明, 加快对全球POI注册中心的数据搜集和分析, 以促进关键领域的研究进展。

Keywords:

• Premature ovarian insufficiency
• hormone therapy
• cardiometabolic health
• bone health
• cognitive health
• reproductive health
• fertility
• oocyte donation

Potential conflict of interest

N. Panay has lectured and/or acted in an advisory capacity for Abbott, Besins, Lawley, Mithra, Mylan, Novo Nordisk, Roche Diagnostics, SeCur, Shionogi, and Theramex. R. A. Anderson has undertaken consultancy work for Merck, IBSA, Roche Diagnostics, KaNDY Therapeutics, and Sojournix Inc. R. E. Nappi had past financial relationships (lecturer, member of advisory boards, and/or consultant) with Boehringer Ingelheim, Ely Lilly, Endoceutics, Gedeon Richter, HRA Pharma, Procter & Gamble Co, TEVA Women’s Health Inc., and Zambon SpA; at present, she has an ongoing relationship with Astellas, Bayer HealthCare AG, Exceltis, Fidia, Merck Sharpe & Dohme, Novo Nordisk, Palatin Technologies, Pfizer Inc., Shionogi, and Theramex. A. J. Vincent has received grant funding, speaker honorarium, or travel support from Besins, Amgen, and Merck. S. Vujovic has no declarations relevant to this manuscript. L. Webber has no declarations relevant to this manuscript. W. Wolfman has undertaken advisory board work for Pfizer, Searchlight, and BioSyent.

Source of funding

Nil.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.